Focus / ADHD
A clear-eyed map of the peptides and nutritional adjuncts being used for attention and executive function — what the literature supports, what the FDA has banned, and where the biohacking consensus is running ahead of the data.
Focus and ADHD are where the peptide literature meets the nootropic community, and the disagreements run deep. Russian clinical use of Semax and Selank is decades old; the FDA calls both prohibited-for-compounding. Dihexa's foundational paper is retracted. Noopept's evidence base is thinner than its reputation. This protocol maps what the human data supports, what the animal and open-label data only hints at, and where the gap between biohacking consensus and regulatory reality matters most.
I.The Retracted 'Miracle' — Dihexa and the Clinical Translation Gap
Dihexa — a small-molecule analogue of Angiotensin IV — became biohacker-famous on the claim it is 'millions of times more potent than BDNF' at inducing synaptogenesis. The mechanism is real: activation of the HGF/c-Met pathway increases dendritic spine density and can rebuild compromised neural wiring in preclinical models.
The part the biohacking write-ups tend to leave out: the foundational 2014 Benoist et al. study making that potency claim has been formally retracted. Dr. Joseph Harding's spin-out Athira Pharma developed a Dihexa derivative, fosgonimeton (ATH-1017), for Alzheimer's. The Phase 2/3 LIFT-AD trial failed its endpoints in late 2024–early 2025 and the program was discontinued for that indication.
In the ADHD context this matters twice over: the marquee synaptogenic peptide of the nootropic stack has no surviving foundational potency citation and no successful human translation. Anything you read about its power should be read against that.
II.Russia's 'Calm Focus' Stack — Semax and Selank as Stimulant Alternatives
Semax and Selank were developed at Russia's Institute of Molecular Genetics and occupy a niche Western medicine has not filled: focus without the arousal and dependency profile of amphetamine-class stimulants.
Semax is a seven-amino-acid analogue of ACTH(4–10), engineered to be devoid of hormonal activity while retaining neuromodulatory effects. A single administration induces a measurable rise in BDNF protein and TrkB phosphorylation — the same receptor axis that mediates long-term potentiation. It is included on Russia's 'List of Vital and Essential Drugs for Medical Application'.
Selank is a tuftsin analogue that engages the GABAergic system. It produces anxiolysis without the sedation, amnesia, or dependency of benzodiazepines. Used together, the pair targets the two failure modes many people with ADHD describe with classical stimulants: the arousal tipping into anxiety, and the crash.
The FDA position is sharper than the Russian clinical record suggests. Both compounds are Category 2 Bulk Drug Substances — prohibited from being compounded for human use — with the agency citing immunogenicity and insufficient human safety data.
Explore This Protocol
Stay Ahead of the Research
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.